Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)
Conditions
Interventions
Placebo
Upadacitinib
Locations
165
United States
Alabama Medical Group, PC /ID# 159836
Mobile, Alabama, United States
Arizona Arthritis & Rheumatology Research, PLLC /ID# 160047
Mesa, Arizona, United States
Sun Valley Arthritis Center Ltd. /ID# 161203
Peoria, Arizona, United States
Duplicate_AZ Arthritis and Rheumotology Research, PLLC /ID# 160006
Phoenix, Arizona, United States
Osteoporosis Medical Center /ID# 161411
Beverly Hills, California, United States
Covina Arthritis Clinic /ID# 159919
Covina, California, United States
Start Date
May 1, 2017
Primary Completion Date
July 23, 2019
Completion Date
September 30, 2024
Last Updated
September 11, 2025
NCT07486960
NCT07536529
NCT07295509
NCT07286058
NCT06100744
NCT04402086
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions